BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

BMO Capital raised the firm’s price target on Schrodinger (SDGR) to $28 from $25 and keeps an Outperform rating on the shares. The ...

Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed ...

In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials ...

Air Quality Index for one’s region can be a handy thing to know, but it’s such a dry and humorless number, isn’t it? Well, all that changes with [Andrew Kleindolph]’s AQI Funnies: a visual ...

Financially stable C4 Therapeutics (CCCC) is worth watching for patient investors, but current lack of definitive data poses ...

The Honda Passport was always the most rugged Honda SUV sold in the United States, with more of an off-roading edge than the ...

The decision to reduce the company's workforce and pause other pipeline activities to focus entirely on COMP360 has been ...

As for the technical readouts of the H-20. It sounds an awful lot like they are on par with the B-2 Spirit and, quite ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, ...

These trials are expected to launch in the first half of 2025, with data readouts expected by year-end. With Phase 2 data for UNVEIL-IT trial also anticipated by the close of 2025, GENFIT will deliver ...